Q-omics provides the consensus-scored CYP2C60P profile across patient tissues and cancer cell-line models. CYP2C60P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CYP2C60P is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, CYP2C60P RNA expression shows 5,137 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, KIRC, and STAD as cancer lineages where CYP2C60P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2C60P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2C60P survival associations across molecular data types. CYP2C60P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2C60P RNA expression–survival associations across cancer types. High CYP2C60P expression shows unfavorable associations in HNSC, KIRC, GBM, MESO, BLCA and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CYP2C60P RNA expression.
This table summarizes CYP2C60P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2C60P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2C60P shows lower tumor expression in KIRC, BRCA and KICH and higher tumor expression in LIHC. The KIRC box plot shows higher CYP2C60P RNA expression in normal versus tumor tissue (log2 FC = −0.114, t-test p = .007).
This table shows molecular features associated with CYP2C60P in patient tissues and cancer cell lines. In patient samples, CYP2C60P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
